MB-12066 is under clinical development by Yungjin Pharm and currently in Phase II for MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes). According to GlobalData, Phase II drugs for MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MB-12066 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MB-12066 overview

MB-12066 (Beta Lapachone) was under development for the treatment of age related macular degeneration, metabolic syndrome, obesity diabetes, hyperlipidemia, atherosclerosis, cardiovascular disease, chronic myelogenous leukemia and erectile dysfunction, MELAS Syndrome and non alcoholic fatty liver disease. The drug candidate is administered orally. The drug candidate is a Sirtuin activator. It is under development for the treatment of primary sclerosing cholangitis. It is administered through oral route.

Yungjin Pharm overview

Yungjin Pharm (Yungjin), a subsidiary of KT&G Corp is a diversified pharmaceutical company. The company specializing in the development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical formulations. Yungjin’s product portfolio encompasses finished pharmaceutical products targeting a wide range of medical conditions, vitamins, minerals, antibiotics, analgesics, antihistamines, anti-fungal medications, total nutrition solutions, and cosmetics. Yungjin operates a research and development institute and a manufacturing facility in Korea. Yungjin offering a diverse array of products and services. Yungjin is headquartered in Seoul, South Korea.

For a complete picture of MB-12066’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.